Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Glioma × Naltrexone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Overweight 2 Obesity 2 Breast Neoplasms 2 Glioma 1 Glioblastoma 1

Interventions

Temozolomide 77 Bevacizumab 45 Radiotherapy 30 Irinotecan 19 Carboplatin 17 Magnetic Resonance Spectroscopy 16 Surgical Procedures, Operative 13 Carmustine 13 Radiation 9 Nivolumab 8 Erlotinib Hydrochloride 8 Thalidomide 7 Lomustine 7 Imatinib Mesylate 7 IL13-PE38 7 Everolimus 7 Aminolevulinic Acid 7 sargramostim 6 Topotecan 6 Radiotherapy, Intensity-Modulated 6 Cyclophosphamide 6 Chemotherapy, Adjuvant 6 vandetanib 5 fluorodopa F 18 5 Vincristine 5 Surveys and Questionnaires 5 Radiosurgery 5 Filgrastim 5 Blood Specimen Collection 5 temsirolimus 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01303835 2015-07-17

Low Dose Naltrexone for Glioma Patients

Duke University

Phase 2 Completed

110 enrolled 9 charts

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡